gloglo

Solving autoimmune disease

One in ten people live with an autoimmune disease, and today’s treatments manage it without addressing the cause. GloGlo uses AI to design drugs that stop the immune attack at its source.

Our platform targets a driver shared by type 1 diabetes, lupus, rheumatoid arthritis, multiple sclerosis and many other autoimmune diseases.

Science

Today’s autoimmune drugs weaken the whole immune system.

Most treatments suppress immunity across the body and leave patients open to infection. The newest approaches, CAR-T and T-cell engagers, go further and wipe out B cells altogether, and CAR-T requires chemotherapy first.

In many patients, the attack is sustained inside the organ, by organized immune structures called tertiary lymphoid structures. They act as local training grounds where B cells are activated and mature into cells that make autoantibodies. No approved drug is built to target them.

  • Type 1 diabetes

    Pancreas

  • Lupus

    Kidney

  • Rheumatoid arthritis

    Joints

  • Sjögren’s disease

    Salivary glands

  • Multiple sclerosis

    Membranes around the brain

Pipeline

We run three research programs on our AI drug design platform.

Program 01

Blocking autoantibody production

Our protein drugs block a step these structures need to produce autoantibodies. Instead of wiping out immune cells, they shut down the attack at its source, so patients keep their B cells and T cells.

  1. Design and lab testingNow to Q1 2027
  2. Lead candidateQ1 2027
  3. Animal studies2027
  4. Development candidateEnd of 2027
  5. IND-enabling studies2028
  6. IND clearance2028
Program 02

Removing disease-driving B cells

Our treatments clear only the B cells driving the disease and leave the rest of the immune system intact.

Program 03

Measuring disease activity

Our blood test shows when autoimmune disease is active and whether a treatment is working.

Team

Our team brings together leading researchers in AI, immunology and therapeutics.

Working papers

Careers

We’re hiring researchers and engineers in machine learning, computational biology and immunology to design drugs for autoimmune disease. We’d love to hear from you.

Contact

For partnering and research inquiries, get in touch with our team.